# Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease

> **NCT01460199** · PHASE1 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 33 (actual)

## Conditions studied

- Stage 3 Chronic Kidney Disease

## Interventions

- **DRUG:** CTP-499
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01460199
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2013-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01460199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01460199, "Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01460199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*